Sales. The chart says it all . Bouncing around. Interesting product. Has an AI element . Partner AstraZeneca is no small company.
Development started before 2016.Going to market this year . Over a 6.5B dollar market to hit
Not with out risk of course .
Many customers we’ve spoken to over the past 6 months gave positive feedback on our technological approach and we arelooking forward to sharing our primary validation data with them. We have set ourselves an ambitious commercialisationschedule for 2024 and expect the customer qualification pipeline to accelerate as we present our APAS® PharmaQCtechnology at a number of key global conferences.
AstraZeneca hosts APAS® PharmaQC showcase at Pharmig Modern Micro Methods 2-day industry event heldat AstraZeneca’s Macclesfield Campus in the United Kingdomo Onsite demonstrations of APAS® PharmaQC in AstraZeneca’s QC microbiology laboratoryo AstraZeneca Presentation: Automated environmental monitoring plate reading powered by AI• APAS® PharmaQC technology presented as best practice to biopharmaceutical industry innovators
Regarding the Quarter, Brent Barnes, CEO and Managing Director said:“The Company finished 2023 completing a financial reset while making solid progress on the updated commercial activationstrategy to expand into the pharmaceutical market. We now expect customer placements to new pharmaceuticalmanufacturing companies to commence in the first half of 2024 calendar year, six months ahead of our previous estimates.Our R&D teams remain on track to finalise the APAS® PharmaQC settle plate product in the first quarter of the 2024 calendaryear. The performance data generated is important to support our commercial launch of the product and initial customer placements
IMO
Add to My Watchlist
What is My Watchlist?
